POLR2L: A Potential Drug Target and Biomarker (G5441)

Target Name: POLR2L

NCBI ID: G5441

POLR2L

POLR2L: A Potential Drug Target and Biomarker

POLR2L (poly (ADP-ribose) polymerase 2-like) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Its unique structure and function make it an attractive target for drug development due to its ability to interact with various signaling pathways and its potential to modulate cellular processes that contribute to the disease.

POLR2L is a key player in the poly (ADP-ribose) polymerase (PARP) pathway, which is a well-established process that involves the production of reactive oxygen species (ROS) and its role in cellular stress response. In response to ROS, PARP enzymes can either convert them into water or repair damaged DNA. POLR2L is a critical enzyme in this pathway that is involved in the repair of damaged DNA.

The poly (ADP-ribose) polymerase pathway is involved in various cellular processes, including DNA replication, repair, and cell survival. Many diseases are associated with disruptions in this pathway, which can lead to the production of ROS and contribute to the development and progression of these diseases. The potential of POLR2L as a drug target arises from its ability to modulate the activity of PARP and reduce the production of ROS.

POLR2L has been shown to be involved in the regulation of cellular processes that are crucial for human health and the development of many diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that increased expression of POLR2L is associated with the development of cancer, neurodegenerative diseases, and cardiovascular diseases. Additionally, the deletion of POLR2L has been shown to protect against the development of these diseases.

In addition to its involvement in the PARP pathway, POLR2L has also been shown to be involved in the regulation of cellular processes that are crucial for the development and progression of neurodegenerative diseases. For example, studies have shown that the expression of POLR2L is involved in the regulation of neurotransmitter synthesis and release, which is crucial for the function of the nervous system. Additionally, the deletion of POLR2L has been shown to cause neurodegenerative diseases, further supporting its potential as a drug target and biomarker for these diseases.

POLR2L has also been shown to be involved in the regulation of cellular processes that are crucial for the development and progression of cardiovascular diseases. For example, studies have shown that the expression of POLR2L is involved in the regulation of cell signaling pathways that are crucial for cardiovascular function. Additionally, the deletion of POLR2L has been shown to cause cardiovascular diseases, further supporting its potential as a drug target and biomarker for these diseases.

In conclusion, the potential of POLR2L as a drug target and biomarker makes it an attractive target for drug development due to its unique structure and function. The ability of POLR2L to interact with various signaling pathways and its potential to modulate cellular processes that contribute to the disease make it an attractive candidate for drug development. Further research is needed to fully understand the role of POLR2L in the development and progression of diseases and to develop effective treatments.

Protein Name: RNA Polymerase II, I And III Subunit L

Functions: DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Common component of RNA polymerases I, II and III which synthesize ribosomal RNA precursors, mRNA precursors and many functional non-coding RNAs, and a small RNAs, such as 5S rRNA and tRNAs, respectively. Pol II is the central component of the basal RNA polymerase II transcription machinery. Pols are composed of mobile elements that move relative to each other. In Pol II, POLR2L/RBP10 is part of the core element with the central large cleft (By similarity)

The "POLR2L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLR2L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets